{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:25:39Z","timestamp":1723767939581},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1707","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The FDA has approved ustekinumab-auub (Wezlana \u2013 Amgen), an interchangeable biosimilar product similar to the interleukin-12 and -23 antagonist Stelara, for treatment of the same indications as Stelara. Wezlana is the first Stelara biosimilar to be approved in the US.<\/jats:p>","DOI":"10.58347\/tml.2024.1707e","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T15:26:10Z","timestamp":1723735570000},"page":"119-119","source":"Crossref","is-referenced-by-count":0,"title":["In Brief: Wezlana \u2014 An Ustekinumab Biosimilar Interchangeable with Stelara"],"prefix":"10.58347","volume":"66","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"37151","published-online":{"date-parts":[[2024,7,22]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T15:26:12Z","timestamp":1723735572000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1707e"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":0,"journal-issue":{"issue":"1707","published-online":{"date-parts":[[2024,7,22]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2024.1707e","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,22]]}}}